0.38 | 1.00%
| Price and Volume | |
|---|---|
| Recent Price | 38.47 |
| 52 Week High | 45.00 |
| 52 Week Low | 29.71 |
| Avg. Daily Vol. (Mil) | 0.58 |
| Beta (3 year) | 0.91 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,524.01 |
| Shares Out (Mil) | 65.61 |
| Float (Mil) | 56.67 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.00 |
| Current Ratio | 3.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 8.93 |
| Price/Book | 10.90 |
| Price/Cash Flow | 136.50 |
| Per Share Data | |
| Earnings | -0.04 |
| Sales | 4.31 |
| Book Value | 3.53 |
| Cash Flow | 0.28 |
| Business Summary | |
|---|---|
| Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the Clinical market, as well as for application in the company's legacy Bio threat and Industrial markets. | |
| General Information | |
| 904 Caribbean Drive
Sunnyvale, CA 94089 |
|
| www.cepheid.com | |
| Industry : Electronics | |
| Sector: Technology | |
| Employees: 717 | |
| CEO: John L. Bishop | |
| Short Interest | |
| Current Month (Mil) | 7.77 |
| Previous Month (Mil) | 7.27 |
| Short Interest Ratio (Days) | 10.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -1.10 |
| Return on Investments | -1.50 |
| Profitability | |
| Gross Margin | 60.60 |
| EBIT Margin | -1.90 |
| Profit Margin | -1.20 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
106.76
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet